To explore the clinical efficacy of Tripterygium wilfordii polyglycosides in the treatment of rheumatoid arthritis(RA)pulmonary interstitial lesion(ILD).Methods:A total of 100 patients with RA-ILD were randomly divided into a control group and a study group，with 50 cases in each group.The control group was treated with prednisone and the study group was treated with Tripterygium wilfordii polyglycosides based on the control group.The total clinical effective rate，symptom scores，erythrocyte sedimentation rate(ESR)，C-reactive protein(CRP)，rheumatoid factor(RF)，lung high resolution CT(HRCT)score，forced vital capacity(FVC)，forced expiratory volume in 1s(FEV1)，FEV1/FVC，matrix metalloproteinase-1(MMP-1)and matrix metalloproteinase-9(MMP-9)levels in peripheral blood and adverse reactions were compared between the 2 groups before and after treatment.Results:Tripterygium wilfordii polyglycosides could significantly reduce the TCM syndrome scores of RA-ILD patients，increase the total clinical effective rate，decrease the levels of ESR，CRP，RF，HRCT and MMP-9，and up-regulate FVC，FEV1，FEV1/FVC and MMP-1.There was no significant difference in the incidence of adverse reactions between the study group and control group(P > 0.05).Conclusion:Tripterygium wilfordii polyglycosides can effectively treat RA-ILD，and its mechanism may be mediated by MMPs，which is worthy of further clinical promotion.